Current Research in Translational Medicine最新文献

{"title":"Preclinical evidence of anti-CD19 CAR-T cell in vitro and in vivo efficacy against CD19-expressing acute myeloid leukemia","authors":"Misa Eugene Norbert ,&nbsp;Alexis Cuffel ,&nbsp;Jérémie Martinet ,&nbsp;Laetitia Jean ,&nbsp;Clara Blondel ,&nbsp;Justine Dehayes ,&nbsp;Aurélie Bisson ,&nbsp;Camille Giverne ,&nbsp;Chrystel Marton ,&nbsp;Ibrahim Yakoub-Agha ,&nbsp;Monica L. Guzman ,&nbsp;Jean-Baptiste Latouche ,&nbsp;Olivier Boyer","doi":"10.1016/j.retram.2026.103567","DOIUrl":"10.1016/j.retram.2026.103567","url":null,"abstract":"<div><h3>Objective</h3><div>Chimeric antigen receptor-modified T cell (CAR-T) therapy has demonstrated remarkable efficacy against refractory B-cell malignancies. This approach is more challenging in non-B-cell hematological malignancies such as acute myeloid leukemia (AML), especially because of target antigen selection difficulty and putative endogenous tumor cell resistance. Nonetheless, some AMLs express CD19, making them potential candidates for anti-CD19 CAR-T (CART19) therapy. This study aimed at establishing preclinical evidence supporting the therapeutic potential of academically developed CART19 cells for the treatment of CD19⁺AMLs.</div></div><div><h3>Methods</h3><div>Luciferase⁺/Green Fluorescent Protein⁺AML-derived Molm-13 cells were transduced with gammaretroviral vectors to express CD19 (Molm-13-CD19), turning them into potential AML targets for CART19, generated from healthy donor T lymphocytes after lentiviral vector transduction. These CD19⁺AML cells could be used <em>in vitro</em> for assessing CART19 specific cytotoxic capacity and <em>in vivo</em> for evaluating CART19 anti-tumor efficacy in immunodeficient mice.</div></div><div><h3>Results</h3><div><em>In vitro</em>, flow cytometry-based cytotoxicity assays evidenced CART19 potent specific killing of Molm-13-CD19 cells, up to 75% at a 2.5:1 effector-to-target ratio after 16 h of coculture. <em>In vivo</em>, CART19 significantly prolonged survival of immunodeficient mice bearing Molm-13-CD19-derived tumors by efficiently killing AML cells, as assessed by bioluminescence imaging. Moreover, in immunodeficient mice lacking MHC to limit graft-versus-host disease, CART19 persisted in bone marrow and spleen up to 90 days post-treatment as evidenced by flow cytometry.</div></div><div><h3>Conclusion</h3><div>These findings demonstrated CART19 efficacy against CD19⁺AML and allowed us to set up a clinical trial which is ongoing (NCT06649227), based on the injection of academically-produced CART19 in strictly selected patients with relapsed/refractory CD19⁺AML.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103567"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of neutrophil extracellular traps in atherosclerosis","authors":"Haoran Zhang ,&nbsp;Yulun Wu ,&nbsp;Qingqing Xiao ,&nbsp;Shuangshuang Gong ,&nbsp;Shixian Shao ,&nbsp;Minghui Ma ,&nbsp;Mo Wang ,&nbsp;Xiaowen Liu","doi":"10.1016/j.retram.2026.103570","DOIUrl":"10.1016/j.retram.2026.103570","url":null,"abstract":"<div><div>Neutrophils extracellular traps (NETs), released by neutrophils, play a core role in the occurrence and development of atherosclerosis (AS) lesions, which components damage endothelium, destabilize plaques by inducing vascular smooth muscle cell death, and exacerbate inflammation and thrombosis via interactions with phagocytes, platelets, and T cells. By blocking the production pathway of NETs and degrading the components of NETs are all feasible methods that could be explored to reduce AS. Here, we reviewed the NETs’ role in AS and their therapeutic potential, offering clinical translation insights.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103570"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147273003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel complex mutation affecting two codons in the exon 10 hotspot region of the MPL gene","authors":"Giovanni Iaquinta ,&nbsp;Alessandro Laganà ,&nbsp;Caterina Tatarelli ,&nbsp;Arianna Di Napoli ,&nbsp;Serena Pasquali ,&nbsp;Agostino Tafuri ,&nbsp;Massimo Breccia ,&nbsp;Paola Grammatico","doi":"10.1016/j.retram.2025.103556","DOIUrl":"10.1016/j.retram.2025.103556","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103556"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing hemoglobin A, F, A2 reference intervals in neonatal cord blood and clinical decision values for β-thalassemia genetic testing","authors":"Sha Li,&nbsp;Jinye Xie,&nbsp;Yuan Tian,&nbsp;Weijia Wang,&nbsp;Juan Wang,&nbsp;Xing’er Wu,&nbsp;Renzhou Li,&nbsp;Man Li,&nbsp;Limin Li","doi":"10.1016/j.retram.2026.103564","DOIUrl":"10.1016/j.retram.2026.103564","url":null,"abstract":"<div><h3>Objective</h3><div>Reference intervals for hemoglobin fractions in neonatal cord blood have been reported; however, there is no consensus on population-specific reference intervals (RIs) and laboratory-derived clinical decision values (CDVs) to guide genetic testing. Therefore, we aimed to establish RIs for HbA, HbF, and HbA2 in neonatal cord blood using a big-data-based indirect method and to determine CDVs for neonatal β-thalassemia genetic testing.</div></div><div><h3>Methods</h3><div>In this retrospective study, we analyzed neonatal cord blood hemoglobin electrophoresis and β-thalassemia genetic testing data collected between January 2013 and November 2024. RIs for HbA, HbF, and HbA2 were established using an indirect method, and CDVs for β-thalassemia genetic testing were determined using receiver operating characteristic (ROC) curve analysis among neonates tested for β-thalassemia.</div></div><div><h3>Results</h3><div>Significant sex-related differences were observed in the RIs for neonatal cord blood hemoglobin. The RIs for HbA, HbF, and HbA2 were 7.8–29.4 %, 70.8–92.0 %, and 0–0.4 % in females and 6.9–27.3 %, 72.1–93.3 %, and 0–0.3 % in males, respectively. HbA2 was not a suitable marker for β-thalassemia genetic testing due to its extremely low levels in neonatal cord blood. The CDVs for β-thalassemia genetic testing were HbA ≤ 8.1 % and HbF ≥ 90.7 % in females and HbA ≤ 7.9 % and HbF ≥ 92.0 % in males, respectively.</div></div><div><h3>Conclusion</h3><div>In this study, we established population-specific RIs for neonatal cord hemoglobin and proposed CDVs indicating that β-thalassemia testing is warranted when HbF ≥ 90.7 % in females or ≥ 92.0 % in males.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103564"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-10+ regulatory B lymphocytes are impacted by intradermal PBMCs therapy in patients with unexplained recurrent pregnancy loss (uRPL)","authors":"Lida Aslanian-kalkhoran ,&nbsp;Mohammad Sadegh Soltani-Zangbar ,&nbsp;Ali Aghebati-Maleki ,&nbsp;Javad Ahmadian Heris ,&nbsp;Mehdi Yousefi ,&nbsp;leili Aghebati-Maleki","doi":"10.1016/j.retram.2026.103565","DOIUrl":"10.1016/j.retram.2026.103565","url":null,"abstract":"<div><h3>Background</h3><div>Following the confirmation of studies on the improvement of pregnancy outcomes after treatment with lymphocytes, this project aimed to assess the effectiveness of this treatment method in patients with unexplained recurrent pregnancy loss (uRPL).</div></div><div><h3>Methods</h3><div>After isolating B cells from 100 uRPL patients, the frequency of IL-10⁺ <em>B</em> cells after treatment was measured by flow cytometry. Real-time PCR was applied to appraise the mRNA expression of microRNA and Programmed death-ligand 1(PD-L1) genes. The measurement of interleukin-10 (IL-10) secretory level in the supernatant medium was performed using the Enzyme-linked immunosorbent assay (ELISA) method.</div></div><div><h3>Results</h3><div>The data demonstrated that the frequency of IL-10⁺ <em>B</em> cells increased after treatment with PBMCs. The expression levels of miR-10a and miR-155 were elevated in patients who received PBMCs treatments, while the levels of miR-16 and miR-21 were decreased. Furthermore, after PBMCs treatment, an increased expression level of PD-L1 was observed. The ELISA results indicated that IL-10 secretion levels increased significantly with PBMC therapy. In the group treated with PBMCs, 33 out of 50 women (66%) achieved a live birth, compared to only 15 out of 50 women (30%) in the control group.</div></div><div><h3>Conclusion</h3><div>In patients with uRPL, PBMCs treatment can enhance the chances of successful pregnancy by positively influencing immune regulatory factors.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103565"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual expression of peripheral blood Alzheimer’s markers, inflammatory cytokines, and cholinergic biomarkers in chronic kidney disease patients with cognitive dysfunction: Therapeutic impact of recombinant human erythropoietin (rHuEPO)","authors":"Vinoth Kumar Ganesan","doi":"10.1016/j.retram.2026.103568","DOIUrl":"10.1016/j.retram.2026.103568","url":null,"abstract":"<div><h3>Background</h3><div>Patients with chronic kidney disease (CKD) are at a significantly increased risk of developing Alzheimer’s disease (AD) and cognitive dysfunction compared to the general population. While recombinant human erythropoietin (rHuEPO) is commonly used to treat anemia in CKD, emerging evidence indicates that it also possesses neuroprotective properties. This study aimed to evaluate the therapeutic impact of rHuEPO on platelet expression of amyloid precursor protein (APP) proteolytic fragments, apolipoprotein E (ApoE), glycogen synthase kinase 3β (GSK3β), total Tau, and phosphorylated Tau species (P-Tau181, P-Tau217, and P-Tau231), along with plasma levels of APP cleaving enzymes, P-Tau217, P-Tau231, inflammatory cytokines, and cholinergic markers in CKD patients with cognitive dysfunction.</div></div><div><h3>Methods</h3><div>A total of 60 CKD patients were enrolled, including 30 without cognitive dysfunction and 30 with cognitive dysfunction, as determined by neuropsychological assessment. Platelet protein expression levels of total Tau, P-Tau181, P-Tau217, P-Tau231, and ApoE were analyzed using Western blotting. Gene expression levels of APP-cleaving enzymes, ApoE, GSK3β, and MAPT in platelets were assessed by RT-PCR. Plasma concentrations of APP-cleaving enzymes, inflammatory cytokines, cholinergic markers, P Tau217, and P-Tau231 were quantified. Results were compared with healthy controls, normocytic normochromic anemia, and AD.</div></div><div><h3>Results</h3><div>CKD patients with cognitive dysfunction showed significant alterations in the expression of platelet proteins (total Tau, P-Tau181, P Tau217, P-Tau231, and ApoE) and related genes (APP cleaving enzymes, ApoE, GSK3β, and MAPT), resembling the molecular profile observed in AD. Additionally, plasma levels of APP cleaving enzymes, inflammatory cytokines, cholinergic markers, and phosphorylated Tau species (P-Tau217 and P-Tau231) were significantly altered in these patients. Notably, after 6 months of rHuEPO therapy, these biomarkers showed marked improvement in CKD patients with cognitive dysfunction.</div></div><div><h3>Conclusion</h3><div>These findings suggest that rHuEPO may offer therapeutic benefits beyond anemia correction, potentially serving as a supportive treatment for cognitive dysfunction in CKD by modulating AD-related peripheral biomarkers.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103568"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An updated meta-analysis of umbilical cord blood to treat cerebral palsy: distinguishing cord blood infusions from mesenchymal stromal cell therapy","authors":"An Duong ,&nbsp;Risa Shorr ,&nbsp;David S. Allan","doi":"10.1016/j.retram.2026.103574","DOIUrl":"10.1016/j.retram.2026.103574","url":null,"abstract":"<div><div>Treatment with umbilical cord blood (UCB) for cerebral palsy (CP) remains promising but experimental and unproven. An updated meta-analysis is needed to assess the efficacy of UCB mononuclear cells (MNCs) in comparison to UCB-derived mesenchymal stromal cells (MSCs) to clarify future directions in the use of UCB to treat CP. An updated systematic review of published controlled clinical trials to November 2024 was conducted and identified ten trials (621 patients; 71% of all patients from 7 trials received UCB-MNCs). Three trials administered UCB-MSCs (30%) and one study compared UCB-MNCs to UCB-MSCs. In one study, MNCs were administered with or without erythropoietin. Eight studies (80%) administered allogeneic cells. Dosage and route of cell administration varied. Clinical outcome reporting was variable, but allowed for meta-analysis of change in GMFM motor scores at 12 months (included 9 groups across 7 studies). Using a random effects model, the standardized mean difference in GMFM scores between baseline and 12 months was higher in the intervention group compared to controls (M= 0.5828, 95% CI=[0.19,0.98], P-value= 0.004). Subgroup analysis using a random-effects model revealed no statistically significant difference in GMFM scores from baseline to 12 months compared to controls in the MNC group (M_A = 0.3225, 95% CI = [-0.19, 0.84], P -value= 0.22), whereas in the MSC group, GMFM scores improved more significantly compared to controls (M_B = 0.9192, 95% CI = [0.33,1.50], P-value = 0.002). In conclusion, infusion of UCB-MSCs appears promising, with improved GMFM scores at 12 months for patients with cerebral palsy. Larger randomized controlled trials that examine MSCs derived from cord blood and other tissues appears worthwhile. Longer follow-up addressing the breadth of relevant clinical outcomes in CP are needed to confirm potential benefits for patients with CP.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103574"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147345632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infections in VEXAS syndrome: a systematic review of the literature","authors":"Syed B Ali ,&nbsp;Carmelo Gurnari","doi":"10.1016/j.retram.2025.103524","DOIUrl":"10.1016/j.retram.2025.103524","url":null,"abstract":"<div><div>Vacuolation, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a multisystem disease for which chronic immunosuppression is needed. Opportunistic infections are common; however, a clear prophylaxis regimen is not defined.</div><div>A systematic review of the literature was undertaken. Six publications with 123 patients were evaluated. Of 86 patients with demographic data; most were males (<em>n</em> = 85, 98.8 %) and median age was 73 years. <em>UBA1</em> mutational status was reported in 80 patients: p.Met41Thr (<em>n</em> = 43, 53.8 %), p.Met41Val (<em>n</em> = 17, 21.3 %) and p.Met41Leu (<em>n</em> = 12, 15.0 %) were most common. In these patients, 48 (60 %) had underlying myelodysplastic syndrome.</div><div>Many of the patients had multiple hospitalizations. Infections were reported as follows: COVID19 (<em>n</em> = 20), Pneumocystis <em>jiroveci</em> pneumonia (PJP) (<em>n</em> = 16), nontuberculous mycobacterium (NTM) species (<em>n</em> = 16), <em>Enterobacteriaceae</em> species (<em>n</em> = 14), <em>Legionella</em> species (<em>n</em> = 13), Varicella Zoster virus (<em>n</em> = 11) and Herpes Simplex Virus (<em>n</em> = 8) infections, respectively.</div><div>Daily prednisolone dose was at, or greater than 10 mg and overall median long term steroid treatment duration was 3.1 years. Notably, for NTM the median daily prednisolone dose was 12.5 mg. Median prednisolone dosing for PJP was only reported in one of the publications, comprising six patients, at 17 mg per day. Where data was available, 45 of the 95 patients (47.3 %) were deceased at last follow-up. Of the 45 deaths, 32 (71.1 %) were attributed to the intercurrent infection.</div><div>In summary, opportunistic infections are commonly reported in VEXAS syndrome. Prophylaxis for such infections remains paramount but no clear consensus on recommendations exists, highlighting the need for prospective studies. Moreover, furthering our understanding of pathophysiology of VEXAS syndrome and impairment in both innate and humoral immunity may clarify its contribution to infections in addition to high background immunosuppressive therapies.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103524"},"PeriodicalIF":3.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-assisted statistical review of 100 oncology research articles: compliance with SAMPL guidelines","authors":"Michal Ordak","doi":"10.1016/j.retram.2025.103544","DOIUrl":"10.1016/j.retram.2025.103544","url":null,"abstract":"<div><h3>Background</h3><div><strong>:</strong> Ensuring accurate statistical reporting is critical in oncology research, where data-driven conclusions impact clinical decision-making. Despite standardized guidelines such as the Statistical Analyses and Methods in the Published Literature (SAMPL), adherence remains inconsistent. This study evaluates the performance of Gemini Advanced 2.0 Flash, an AI model, in assessing compliance with SAMPL guidelines in oncology research articles.</div></div><div><h3>Methods</h3><div><strong>:</strong> A total of 100 original research articles published in four peer-reviewed oncology journals (October 2024–February 2025) were analyzed. Gemini Advanced 2.0 Flash assessed adherence to ten key SAMPL guidelines, categorizing each as \"not met,\" \"partially met,\" or \"fully met.\" AI evaluations were compared with independent assessments by a statistical editor, with agreement quantified using Cohen’s Kappa coefficient.</div></div><div><h3>Results</h3><div>The overall weighted Kappa coefficient was 0.77 (95 % CI: 0.6–0.94), indicating substantial agreement between AI and manual assessment. Full agreement (Kappa = 1) was found for four guidelines, including naming statistical packages and reporting confidence intervals. High agreement was observed for specifying statistical methods (Kappa = 0.85) and confirming test assumptions (Kappa = 0.75). Moderate agreement was noted for summarizing non-normally distributed data (Kappa = 0.42) and specifying test directionality (Kappa = 0.43). The lowest agreement (Kappa = 0.37) was observed in multiple comparison adjustments due to missing justifications for post hoc tests.</div></div><div><h3>Conclusion</h3><div><strong>:</strong> AI-assisted evaluation showed substantial agreement with expert assessment, demonstrating its potential in statistical review. However, discrepancies in specific guidelines suggest human oversight remains essential for ensuring statistical rigor in oncology research. Further refinement of AI models may enhance their reliability in scientific publishing.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103544"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of pre- and post-transplant concentrations of citrulline, zonulin, and calprotectin in children undergoing allogeneic hematopoietic cell transplantation","authors":"Pejman Rohani ,&nbsp;Faezeh Tejareh ,&nbsp;Amir Ali Hamidieh ,&nbsp;Maryam Behfar ,&nbsp;Mohammad Hassan Sohouli","doi":"10.1016/j.retram.2025.103525","DOIUrl":"10.1016/j.retram.2025.103525","url":null,"abstract":"<div><h3>Background</h3><div>Allogeneic hematopoietic cell transplantation (allo-HCT) is a life-saving treatment for pediatric patients but is often associated with severe gastrointestinal complications. Identifying reliable biomarkers of gut integrity and inflammation is crucial for early detection and management of these issues. This study evaluates pre- and post-transplant levels of citrulline, zonulin, and calprotectin in pediatric allo-HCT patients.</div></div><div><h3>Methods</h3><div>A prospective cohort study was conducted on 100 pediatric patients at the Children’s Hospital from 2023 to 2025. Citrulline, zonulin, and calprotectin levels were measured at baseline (pre-transplant), 3 months, and 6 months post-transplant.</div></div><div><h3>Results</h3><div>Calprotectin and zonulin levels peaked at 3 months post-transplant (calprotectin: 123 ± 40 µg/g, <em>p</em> &lt; 0.001; zonulin: 90.69 ± 20.32 ng/mL, <em>p</em> = 0.001) and declined by 6 months (calprotectin: 90.05 ± 30.27 µg/g; zonulin: 70.74 ± 15.38 ng/mL). Citrulline levels decreased from 25.49 ± 8.22 µM at baseline to 20.39 ± 5.52 µM at 6 months (<em>p</em> = 0.004). Elevated calprotectin and zonulin levels were strongly associated with severe GVHD (Grade III-IV: calprotectin 153.25 ± 51.81 µg/g, <em>p</em> = 0.001; zonulin 110.05 ± 25.33 ng/mL, <em>p</em> = 0.002) and higher grades of diarrhea and mucositis. Patients with obesity (BMI &gt; 30) had significantly higher biomarker levels. Multiple hospital readmissions were also associated with elevated biomarker levels (<em>p</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>Citrulline, zonulin, and calprotectin are promising biomarkers for assessing GI toxicity and inflammation in pediatric allo-HCT recipients. Their levels correlate with the severity of post-transplant complications, nutritional status, and clinical outcomes.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"Article 103525"},"PeriodicalIF":3.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}